P
Peter F J Ryan
Researcher at Alfred Hospital
Publications - 36
Citations - 1736
Peter F J Ryan is an academic researcher from Alfred Hospital. The author has contributed to research in topics: Arthritis & Rheumatoid arthritis. The author has an hindex of 16, co-authored 36 publications receiving 1681 citations. Previous affiliations of Peter F J Ryan include Box Hill Hospital & Monash University.
Papers
More filters
Journal ArticleDOI
LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis a phase I randomized, double-blind, placebo-controlled, proof-of-concept study
Mark C. Genovese,F. Van den Bosch,S. A. Roberson,S. Bojin,I. M. Biagini,Peter F J Ryan,J. Sloan-Lancaster +6 more
TL;DR: LY2439821 added to oral DMARDs improved signs and symptoms of RA, with no strong adverse safety signal noted, and supports neutralization of IL-17 as a potential novel goal for the treatment of RA.
Journal ArticleDOI
Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis.
E. Romas,E. Romas,Natalie A. Sims,Daphne K. Hards,Mandy Lee Lindsay,Julian M.W. Quinn,Peter F J Ryan,Colin R. Dunstan,T. John Martin,Matthew T. Gillespie +9 more
TL;DR: It is demonstrated that short term Fc-OPG treatment has powerful anti-erosive effects, principally on bone, even though synovitis is not affected, and the potential utility of disrupting RANK signaling to preserve skeletal integrity in inflammatory arthritis is indicated.
Journal ArticleDOI
Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate
Rachelle Buchbinder,Melissa Naughton Barber,Louise Heuzenroeder,Anita E. Wluka,Graham G. Giles,Stephen Hall,A. Harkness,Daniel Lewis,Geoffrey O. Littlejohn,M Miller,Peter F J Ryan,Damien Jolley +11 more
TL;DR: Compared with the general population, methotrexate-treated RA patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and lung cancer, and there may be a role for regular skin cancer screening for all RA patients, particularly those receiving immunosuppressive therapy.
Journal ArticleDOI
Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis.
E. Romas,Olga Bakharevski,Daphne K. Hards,Vicky Kartsogiannis,Julian M.W. Quinn,Peter F J Ryan,T. John Martin,Matthew T. Gillespie +7 more
TL;DR: Focal bone erosion in CIA is attributed to cells expressing definitive features of osteoclasts, including CTR, and the expression of RANKL by cells within inflamed synovium suggests a mechanism for osteoclast differentiation and activation at sites of bone erosion.
Journal Article
Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice.
Rachelle Buchbinder,Stephen Hall,P. N. Sambrook,G. D. Champion,A. Harkness,D. Lewis,Geoffrey O. Littlejohn,M. H. Miller,Peter F J Ryan +8 more
TL;DR: It is concluded that MTX therapy for RA is well tolerated and maintains effectiveness for at least 70 months.